Beyond Borders Ppt
-
Upload
anirudh89p -
Category
Documents
-
view
216 -
download
0
Transcript of Beyond Borders Ppt
-
8/8/2019 Beyond Borders Ppt
1/25
-
8/8/2019 Beyond Borders Ppt
2/25
Financial crisis
Application of biotech to all the fields
Emerging biotech cos got affected verybadly
Started working on pay rolls, selling assetsetc.
Worried about the recovery Emergence of New Normal
Formulation of new & sutainable businessmodels
-
8/8/2019 Beyond Borders Ppt
3/25
Crisis started to settle after some time
Financing improved
India & China: least effected by the crisis
-
8/8/2019 Beyond Borders Ppt
4/25
E&Y predicted that therell be a sharpreduction in cos numbers but that didnt
happen Investors are looking for de-risked
investments and a challenging & healthymarket environment
Companies shrunk only 11% as againstthe predictions of 33% decline
-
8/8/2019 Beyond Borders Ppt
5/25
Most of the US & Canadian cos had lesscash on hand during the crisis
Key driver of survival: ability to operatemore efficiently
Efficient ways to deploy scarce capital,
defray high costs of R&D, share risks &rewards
-
8/8/2019 Beyond Borders Ppt
6/25
VCs have funded portfolios of thecompanies that have the potential to
grow into fully integrated, self sustainingenterprises.
VCs in crisis: capital constraints,practically non existing IPOs and longexit options
-
8/8/2019 Beyond Borders Ppt
7/25
Increasing efficiency: funding vs innovation
Decreasing R&D costs and increasing its
success rate Reality: pharma cos are divesting
Asset centric model developed by IndexVentures
Patients need drugs, not the companies
Investors need efficient ways to deploycapital
-
8/8/2019 Beyond Borders Ppt
8/25
Pharma cos are innovating
Some cos are sticking to drug discovery
and others are expanding (for ex. fromgenerics to nutraceuticals)
Collaboration between biotech and
pharma companies Option based transactions and buying
only if the clinical trial has beensuccessfully completed
-
8/8/2019 Beyond Borders Ppt
9/25
Govts pressurized companies on pricingpolicies
Drivers of this trend
1. Growing costs2. Desire to penetrate to greater citizenry Budgetary pressures on theGovt due to low
tax revenues
In US, health insurance is tied to employmentstatus Widespread layoffs -> increased the no. of
people at the risk of losing access tohealthcare
-
8/8/2019 Beyond Borders Ppt
10/25
Drug development is time consuming &expensive
Biotech cos depended majorly on1. VCs
2. Public markets &
3. Pharma companies Working with 3rd parties is not just to slash
costs but it also helps in other ways
-
8/8/2019 Beyond Borders Ppt
11/25
Five guiding principles for the newnormal
1. Seize funding opportunities2. Capital efficiency matters
3. If you build, will they pay?
4. Collaborate effectively5. Differentiate your assets
-
8/8/2019 Beyond Borders Ppt
12/25
Innovation in Biotechnology
Role of public policy
Ex: Protection of IPs & Stem Cell funding inBushs regime
FIPNet by Elli Lilly. 3 broad areas
1. Functional outsourcing
2. Novel ways to discover & developmolecules
3. Equity investments & partnerships
-
8/8/2019 Beyond Borders Ppt
13/25
-
8/8/2019 Beyond Borders Ppt
14/25
Opportunities: Western cos focusing onreducing head counts and R&D costs
India & China: Centres of the growth Challenges for western cos:
understanding local market, local
culture, available resources, infra andGovt policies
-
8/8/2019 Beyond Borders Ppt
15/25
Dominated by TCMs
Scenario is slowly changing
Growth rate of 29% from 2006-09 andwould surpass Germany & France as #3drug maker by 2011 (IMS Survey)
Highly attractive outsourcing destination Health Reforms: worth $124 billion
insurance for non-employed urban &rural population
-
8/8/2019 Beyond Borders Ppt
16/25
China updated its EDL 307 medicines 2/3rd : products discovered outside China 1/3rd : TCM Govt regulated pricing Biomedicine is their strategic focus as per
11th five year plan Spending $9.2 b on technologies Accelerated process for new drug
approvals IP reforms; Science Parks etc
-
8/8/2019 Beyond Borders Ppt
17/25
Opportunities:x Liberalized IP regime
x Highly skilled work forcex Lower manufacturing and R&D costs
x Growing demand for healthcarex Not effected by recession
xLess reliant on capital from investors
-
8/8/2019 Beyond Borders Ppt
18/25
NBRA Bill Backed by controversial Bt Brinjal issue About to be presented in parliament in this
winter session of parliament Opposed by a strong lobby of GM seed
manufacturers National policy on vaccines being drafted
by ICMRx Equal importance to PSUsx To focus on manufacturing & affordability of
vaccinesx CROs require DCGIs approval
-
8/8/2019 Beyond Borders Ppt
19/25
Bt Brinjal would have been the first everGMfood crop to be grown on a large scale in theworld
India is working on rice, mustard, cauliflowerand peas Bt Brinjal failure could hinder 40 applications in
the process DCGI approved stem cell induced clinical trials
by StemPeutics in India (2nd after US) CordLife established cord cell banks in India Fortis tied up with Biek Biotech to conduct
clinical trials for a stem cell therapy
-
8/8/2019 Beyond Borders Ppt
20/25
Infra Development:x PPP models in establishing Biotech Parks &Clusters
x 3 Biotech clusters @Mohali, Faridabad &Bangalore
x Marine biotech research institute @ Kerala with@$45million
x Biotech SEZs in APx Karnataka:Millenium Biotech Policy II
x 5 biotech parks
Himachal Pradesh & Goa are also considering under PPPmodels
-
8/8/2019 Beyond Borders Ppt
21/25
Financing: Not by VCs & PE Funds
In US, VC funding was reduced from
$120m to $24million during recession Avasthagen planned an IPO in 2010 in
India; expected to raise $13-15 million
Investments: US based, Biogen Idecannounced to enter with its completedrug portfolio into India
-
8/8/2019 Beyond Borders Ppt
22/25
Deals:x Sanofi Aventis bought Shantha Biotechnics for
$660million
x Merck acquired Bangalore genei for $8.8millionx Daiichi Sankyo acquired Ranbaxy & Biovel Life
Sciences
x Advanta India acquired US based, CrossbytonSeed Co
x Transgene Biotek entered a licensing agreementwith DRL on obesity management drug
x BristolMyers Squibb along with Syngene had setupa integrated drug discovery center @ Biocon Park
x And several other deals
-
8/8/2019 Beyond Borders Ppt
23/25
Biosimilars: The next big opportunityx Reliance Life Sciences, Shantha, Panacea,
Biocon, Wockhardt and Intas Pharma havebeen developing new arenas in this area
x Oral Insulin by Biocon; to be US market by 2011
x Cipla formed a JV with Chinese firm forresearch in this field
-
8/8/2019 Beyond Borders Ppt
24/25
After financial crisis, US companies arelooking to acquire the companies in new
geographies in niche segments To move up the value chain Indian cos
has to continuously improve novel drugs& diversify its portfolio
4As and 3Ps strategy
-
8/8/2019 Beyond Borders Ppt
25/25
Thank YouBY_
ANIRUDH PULUGURTHAPGDM-BT (0911-01)
INSTITUTE OF PUBLIC ENTERPRISE